Rural Health Information Hub Latest News

NIOSH COVID-19 Update

As part of NIOSH’s efforts to keep stakeholders up to date on the CDC and NIOSH COVID-19 response, below is a summary of new information posted:

HRSA Plans October 5 Release of 2019 National Survey of Children’s Health Data

HRSA will release 2019 data from the National Survey of Children’s Health (NSCH) on October 5, which is also National Child Health Day. The NSCH provides the latest national and state-level data on the health and health care needs of children as well as information about their families and communities.

Survey topics include:

  • Children’s physical and mental health;
  • Health insurance status;
  • Access to and use of health care services, including:
    • Receipt of preventive and specialty care;
    • Patient-centered medical home; and
    • Services to support transition to adult health care for adolescents;
  • Lifetime exposure to adverse childhood experiences, and more.

The NSCH is funded and directed by HRSA’s Maternal and Child Health Bureau and conducted by the U.S. Census Bureau, which oversees sampling, survey administration and the production of a final data set for public use.

Look for the release on our social media channels (@HRSAgov), and like and share to show your support of Child Health Day.

Learn more about the National Survey of Children’s Health.

Rates of Alcohol-induced Deaths Among Adults Aged 25 and Over in Urban and Rural Areas: United States, 2000–2018

October 2, 2020| Data Brief No. 383

Select key findings
Data from the National Vital Statistics System, Mortality

  • Age-adjusted rates of alcohol-induced deaths among adults aged 25 and over were stable from 2000 to 2006, then increased 43% from 10.7 per 100,000 in 2006 to 15.3 in 2018.
  • For both males and females, alcohol-induced death rates increased at a greater rate between 2000 and 2018 in rural compared with urban areas.

Keywords

urban–rural, trends, health disparities, National Vital Statistics System-Mortality (NVSS-M)

For more information, visit the full report

Full Report in HTML > 

Full Report in PDF >

Draft Viral Hepatitis Strategic Plan 2021-25 Open for Comments

The U.S. Department of Health and Human Services (HHS) has released a draft Viral Hepatitis National Strategic Plan: 2021-2025, which will serve as a roadmap to hepatitis elimination. The plan is available for public comment until Oct. 8, 2020 at 5:00 pm. The plan provides a framework to eliminate viral hepatitis as a public health threat to the U.S. and features five primary goals:

  • Prevent New Hepatitis Infections
  • Improve Viral Hepatitis-Related Health Outcome of People with Viral Hepatitis
  • Reduce Viral Hepatitis-Related Disparities and Health Inequities
  • Improve Viral Hepatitis Surveillance and Data Usage
  • Achieve Integrated, Coordinated Efforts that Address the Viral Hepatitis Epidemics Among All Partners and Stakeholders

HHS is looking for input on whether the plan’s goals, objectives and strategies appropriately address the viral hepatitis epidemic and whether there are any critical gaps. Comments can be submitted to Hepatitis Plan CommentsClick here to read the whole plan.

Million Hearts® 2nd Edition Hypertension Control Change Package

Million Hearts® 2022, a national initiative co-led by the Centers for Disease Control & Prevention (CDC) and the Centers for Medicare and Medicaid Services (CMS), strives to prevent one million heart attacks and strokes within five years by focusing on undiagnosed hypertension, cholesterol management, and tobacco use. The Million Hearts Hypertension Control Change Package published in 2015 has been updated. Click here to download the Hypertension Control Change Package. Don’t forget to visit the Million Hearts website.

The Impact of COVID-19 on Latino Health

This webinar brings together experts to explore the impacts of systemic racism and social and economic inequalities on the health and well-being of Latinos, and to provide effective strategies for addressing these challenges during the COVID-19 pandemic and beyond. The expert panelists discuss:

  • The disproportionate impact of COVID-19 on Latino communities and how unemployment, uninsurance, immigration status and limited English proficiency have been the strongest predictors of COVID-19 cases
  • The diverse history of Latinos in the United States and the need for more inclusion and representation of Latinos and other communities of color in clinical trials and studies
  • How a health plan in Florida is partnering to implement community-based primary care to meet the cultural and linguistic needs of the diverse Latino population in the state

View the National Institute for Health Care Management (NIHCM) infographic on Latino health & COVID-19; available in English and Spanish. View NIHCM’s recent infographic and webinar on the impact of COVID-19 on the health of Black Americans.

FDA Issues Updates on Dental Amalgam

The Food and Drug Administration (FDA) provided updated recommendations on Sept. 24, 2020 about the use of dental amalgam. The information potentially has a large impact on dentistry and public health dental programs. For more information, visit these links:

However, the American Dental Association (ADA) News reported on Sept. 24, 2020 that the ADA “reaffirmed its position that dental amalgam is a ‘durable, safe and effective’ restorative material in response to the U.S. Food and Drug Administration’s Sept. 24 statement that existing evidence shows that dental amalgam is not harmful to the general population and treatment options should be thoroughly discussed by the patient and dentist.”

Where Potential COVID-19 Vaccines Stand in the U.S.

Four vaccines for the novel coronavirus are now in late-stage testing in people in the United States. Here are some details:

  • Johnson & Johnson vaccine – The vaccine uses noninfectious adenovirus, a common cold virus, to deliver a gene from the novel coronavirus to human cells and produce copies of the SARS-CoV-2 protein, potentially priming immune cells to fight infection. The vaccine is being tested as a single dose and can be stored refrigerated for at least three months, potentially alleviating some of the concerns about the logistics of distribution.
  • Moderna vaccine – Messenger RNA, genetic material carrying information about a viral protein, is delivered to cells that produce the protein, which the immune system is then trained to recognize. RNA vaccines are a newer technology, favored for their potential speed in development, but none have been approved for humans for any virus. The vaccine is being given in two doses and is stored frozen.
  • Pfizer vaccine – This vaccine is also an mRNA vaccine being tested as two doses. It currently requires storage at -70°C (-94°F). Pfizer has an initial agreement with the U.S. government for 100 million doses if the vaccine is approved, with an option for 500 million more doses.
  • AstraZeneca/Oxford University vaccine – Similar to the Johnson & Johnson vaccine, this candidate is a viral vector vaccine but uses a different adenovirus. The vaccine’s trial in the U.S. is currently paused after a “suspected adverse event” in a participant in a U.K. trial of the vaccine. It is being given in two doses and is expected to require refrigeration.

Amidst growing public skepticism and distrust of vaccines, the FDA is planning to tighten requirements for assessing a vaccine’s safety and effectiveness, the Washington Post reported.